Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07199270 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 30, 2025 (before its estimated September 18, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups
Trial Details
NCT Number NCT07199270
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Health Adult Subjects
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov